InvestorSoup.com: CYCC's total revenues for third-quarter of 2009 decrease by 14%

InvestorSoup.com announces an investment report featuring Cyclacel Pharmaceuticals Inc. (Nasdaq:CYCC). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

The full report is available at: http://www.investorsoup.com/lp/CYCC

Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup

Cyclacel Pharmaceuticals Inc. (CYCC) is a development-stage biopharmaceutical company engaged in the discovery, development and commercialization of mechanism-targeted drugs to treat human cancers and other serious disorders. The Company markets, directly in the United States, Xclair Cream for radiation dermatitis and Numoisyn Liquid and Numoisyn Lozenges for xerostomia through its wholly owned subsidiary, ALIGN Pharmaceuticals LLC. CYCC focuses primarily on the development of orally available anticancer agents that target the cell cycle with the aim of slowing the progression or shrinking the size of tumors.

Message Board Search for CYCC: http://www.boardcentral.com/boards/CYCC

In the report, the analyst notes:

"Total revenues for the third quarter of 2009 were $0.2 million, representing a decrease of 14% compared to $0.3 million for the same period in 2008. These revenues were mainly attributable to sales of the Xclair® and Numoisyn® products.

"CYCC recently announced that a newly published study demonstrates that the Company's seliciclib (CYC202 or R-roscovitine), an orally available inhibitor of multiple cyclin-dependent kinases (CDKs), reversed resistance to the aromatase inhibitor letrozole (Femara(R)) and killed hormone receptor positive breast cancer cells that had become insensitive to the effects of letrozole. The new study was published in the current edition of Clinical Cancer Research, a journal of the American Association for Cancer Research. Seliciclib is currently in phase 2 clinical trials for non-small cell lung cancer and nasopharyngeal cancer."